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Background: The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular
events. In an effort to gain insight into the utility of CAC for coronary artery disease (CAD) screening in cancer
patients with heart disease, we sought to determine the presence and burden of CAC detected on routine chest
CT in patients referred to a cardio-oncology clinic, comparing them to a conventional cardiology clinic with the
general population as controls.
Methods: Patients from the cardio-oncology clinic, general cardiology clinic, and the general clinic population at
Rush University Medical Center who had a chest CT as part of their previous treatment were identified. Each CT
scan was evaluated for presence, extent, and severity of CAC by 3 independent readers.
Results: In multivariate analysis, when compared with cardio-oncology clinic, CAC was more prevalent in the CT
scans of cardiology patients (p = 0.04), but not the general clinic population (p = 0.5); CAC extent (p = 0.05) and
severity (p = 0.05) was significantly higher in the cardiology patients but the extent (p = 0.05) and severity (p = 0.92)
was similar in the general clinic population.
Conclusion: Despite being matched by age and sex, controlling for other major cardiovascular risk factors, patients
referred to our cardio-oncology clinic had similar and less prevalent/severe CAC burden compared with the general
population and conventional cardiology clinics respectively. Whether this translates to less utility of CAC for CAD
screening, or to less overall coronary events in a cardio-oncology clinic, is of interest.
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Advancements in oncological treatments over the past
few decades, including chemotherapeutics, radiation
therapy and anti-cancer signaling inhibitors, have greatly
improved the survival outcome of patients with cancer.
Unfortunately, many of these treatment options carry
significant risk of cardiovascular complications, espe-
cially among patients with underlying cardiovascular
disease (CVD) [1]. Additionally, survivors of several
types of cancers have been shown to have an increased* Correspondence: Tokwuosa@rush.edu
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years, the field of cardio-oncology has emerged in an
effort to optimize outcomes in cancer patients with heart
disease. Cardio-oncologists work both to treat cardiovas-
cular complications that develop following cancer treat-
ment, and also to identify patients who are at risk of
developing cardiovascular issues in order to help safely
guide cancer treatment and possibly limit morbidity and
mortality associated with cardiotoxic therapies [4].
Assessing the presence and burden of coronary artery
calcium (CAC) is an attractive option for assessing
cardiac risk in a cardio-oncology clinic as cancer
patients often undergo routine screening chest CT scans
in which CAC is readily detected. To this end, there is
very strong data showing that higher CAC burden
(assessed by Agatston scores measured by gated CTle is distributed under the terms of the Creative Commons Attribution 4.0
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presence and degree of CAC has been shown to
reflect the overall atherosclerotic burden and is corre-
lated with the presence of coronary stenosis [7]. In
asymptomatic patients, CAC-based models have been
shown to predict future cardiovascular events [8, 9]
and mortality [10], independent of the classic cardio-
vascular risk factors. Inclusion of the CAC score into
cardiac risk stratification has been shown to predict
coronary events beyond the traditional Framingham
risk factors across all racial groups [11] and particu-
larly in intermediate risk groups, in whom clinical
decision-making is most uncertain [12]. Furthermore,
the absence of CAC is associated with higher survival
and effectively allows a patient to remain classified as
low risk for a period of 15 years [13].
It is notable that CAC is identifiable on non-cardiac
chest CT, such as those used for screening and sta-
ging purposes in cancer patients. In fact, CAC identi-
fied on a routine diagnostic chest CT scan has been
found to predict cardiovascular events with an ad-
justed risk of CVD events that was almost 4 times
higher among patients with severe CAC in one study
[14]. In one study of 60 patients, the correlation coef-
ficients between gated CT for Agatston CAC scoring
and non-gated CT for routine chest examinations
were 0.95, 0.97 and 0.98 for volume, mass and Agat-
ston values, respectively [15]. Findings were similar in
the National Lung Screening Trial (NLST) of 1575
CT scans [16]. In another study, the sensitivity and
specificity of routine chest CT scanning for detecting
positive CAC scores were 96.4 % and 100 %, respect-
ively [17]. Nonetheless, the use of CAC in assessing
cardiac risk in cancer patients having undergone
cancer therapy, is unknown.
In our study, we aimed to compare the presence and
burden of CAC seen on routine chest CT scans in
patients referred to a cardio-oncology clinic. We postu-
lated that information gleaned from our study would
provide some insight into the burden of CAD – and
therefore projected burden of cardiovascular events
based on CAC – in our post treatment cancer patients
with heart disease, compared with a regular cardiology
clinic, and using the general population as controls. This
would also provide some initial data on the utility of
CAC – performed on surveillance chest CT scans – for
coronary artery disease (CAD) screening in cancer pa-
tients with heart disease. Furthermore, if these chest CT
scans obtained for other (non-cardiac) reasons are found
to be useful screening tools in this population, one could
possibly avoid radiation exposure associated with other
screening modalities, such as stress myocardial perfusion
imaging, coronary CT angiography, and dedicated CT
screening for CAC by the Agatston scoring system.Methods
The cases for the current study were identified from
referrals made to the cardio-oncology clinic at the Rush
University Medical Center in Chicago, IL. Patients aged
20–79 years with a history of malignancy who visited the
cardio-oncology clinic in the time period of January to
June 2014, and who had a chest CT performed as part
of their cancer diagnostic/surveillance regimen, were
eligible for the study. In order to obtain a comprehensive
view of the cardio-oncology clinic population, we in-
cluded all types of cancer diagnoses and did not exclude
patients with known CAD or other heart disease. Our
case population was then matched by age, sex and date
of chest CT to patients with no cancer history who vis-
ited the conventional cardiology clinic at Rush, as well
as to a second group of controls matched by age, sex
and date of chest CT with no cancer history selected
from the general clinic population of patients at Rush.
The control groups consisted of both inpatients and
outpatients who underwent chest CT imaging not spe-
cifically performed for oncologic staging or heart disease.
The study was approved by the Rush University Institu-
tional Review Board, and informed consent was waived
due to the retrospective nature of the study.
Information about each patient was collected through
a retrospective review of the electronic medical record
(EMR). Information regarding patient demographics,
cardiac risk factors, medication use and known history
of coronary artery disease, myocardial infarction, cor-
onary artery bypass graft, stent placement and end-
stage renal disease were recorded. For patients with
cancer, the date of diagnosis, type of cancer, and history
of treatment with radiation and/or chemotherapy were
also recorded.
Each chest CT was evaluated for presence, extent, and
severity of CAC by three, experienced readers who were
blinded to clinical information and the purpose of the
study, including a board certified radiologist, and two
cardiologists: with board certifications in cardiac CT. In
an effort to mimic daily clinical practice, we chose to
include CT scans from a variety of different CT imaging
protocols. The CT imaging technique and protocols
remained the same at our institution throughout the
period of the study. All CT scanners were multi-detector
spiral CT (MDCT) scanners with 16, 64 or higher order
row systems with similar in-plane resolution. Four separ-
ate models of CT scanners were used including a Philips
Brilliance 64 (Eindhoven, Netherlands), GE Bright Speed
Profile 16 (Waukesha, Wisconsin), Siemens Definition
AS (Erlangen, Germany), and Siemens Somatom De-
finition Flash (Erlangen, Germany). All images were ob-
tained with single breath hold technique, using thin
section acquisition with 3 mm slice thickness or less,
consistent with the varied clinical reasons for the scan.
Brann et al. Cardio-Oncology  (2016) 2:7 Page 3 of 7A 120 keV tube voltage was applied in the majority of
cases, although a range of 80 keV to 140 keV was used
(with those platforms equipped with keV dose modula-
tion). Image acquisition was obtained with optimization
of radiation dose, utilizing angle dependent dose modu-
lation. Image reconstruction was performed utilizing
medium and higher frequency reconstruction kernels
with respective mediastinal and lung windows. Images
were interpreted with the mediastinal reconstructions.
None of the studies were electrocardiographically pro-
spectively triggered or retrospectively gated.
The chest CT scans were reviewed for the presence,
extent, and severity of CAC within the left main coronary
artery (LMCA), left anterior descending (LAD), left cir-
cumflex coronary artery (LCX) and right coronary artery
(RCA) using a previously published semi-quantitative
visual grading scale [18]. Each vessel was given a score of
0 to 3 for extent defined as 0 = no foci; 1 = focal, a single
focus; 2 =moderate, >1 focus; or diffuse = 3, foci in prox-
imal, mid-, and distal segments. Each vessel was also
given a score of 0 to 3 for severity defined as 0 = no
foci, 1 = mild, 2 = moderate and 3 = severe. The scores
for severity of each vessel were summed to assign a
total CAC severity score for each patient (0–12).
Baseline characteristics were compared in univariate
analysis. Logistic regression was performed to compare
differences in CAC presence between groups while
linear regression was used to assess the relationship
between CAC severity and all 3 groups, adjusting for
race, body mass index (BMI), cardiovascular risk factors,
and use of cardiac medications. A time-dependent
variable (from cancer therapy to date of CT scan) was
also introduced into the models as a covariate. Further-
more, inter-observer variability between readers was
assessed using linear regression. Data are presented as
mean value ± 1 SD, and P value < 0.05 is considered
statistically significant.
Results
A total of 83 patients from the cardio-oncology clinic
met the inclusion criteria and were included in this
study. The mean age was 60 years (range 23–69) and
47 % were men (Table 1). The most common types of
cancer represented were breast cancer (27.7 %), lymph-
oma (15.7 %), lung cancer (13.3 %) and gynecologic
cancers (13.3 %) – Table 2. A history of treatment with
chemotherapy was present in 76 of the 83 patients
(91.6 %). A total of 33 (39.8 %) patients received
radiation therapy, out of which 24 received chest wall
radiation – 7 of these patients had lung cancer, 5 with
lymphoma, 6 with left-sided breast cancer, and 6 with
right-sided breast cancer. The mean time from radiation
therapy to time of chest CT for patients receiving
radiation to the left side of the chest was 1648 days(1327 days for left-sided breast cancer, 4145 days for
lymphoma and 184 days for patients with lung cancer).
Unfortunately, data regarding the dose of radiation
received by each patient were not available. A total of 4
patients, out of the 18 patients who received left chest
radiation, received radiation therapy prior to the ins-
titution of modern, cardiac dose limiting techniques.
The most common reasons for referral to the cardio-
oncology clinic were cardiomyopathy (24.1 %), manage-
ment of cardiovascular risk factors during chemotherapy
(19.2 %), and hypertension (10.8 %). The average amount
of time from the date of cancer diagnosis to the date of
the chest CT used was 4.9 years (median 1.5 years). Out
of the 83 cardio-oncology patients, 79 were undergoing
active therapy at the time of the chest CT scan and 4
were in remission (average 16.25 years since last cancer
treatment). Of those undergoing active therapy, 7 were
being treated for a second malignancy, after having
completed treatment for a separate malignancy on aver-
age 12.4 years prior. The baseline characteristics and
cardiovascular risk factors present in each group are
detailed in Table 1. In univariate analysis, despite
matching for age and sex at baseline, the conventional
cardiology group had higher rates of cardiovascular
disease and risk factors, and were less likely to be white
than the cardio-oncology clinic and general clinic
population group.
A total of 249 chest CT scans were each reviewed
separately by three readers. The findings of the three
readers demonstrated excellent agreement in the total
CAC severity score, with inter-observer correlation
coefficients of 0.92, 0.93 and 0.97 for each 2 of 3
readers (p < 0.01).
CAC was found to be present in 110 of the 249 total
patients included in this study: 35 patients (42 %) from
the cardio-oncology clinic, 40 patients (48 %) from con-
ventional cardiology and 35 patients (42 %) from the gen-
eral clinic population. In multivariate analysis (Table 3),
the presence of CAC was significantly lower in the cardio-
oncology clinic compared with the conventional cardi-
ology clinic (OR 0.334; 95 % CI: 0.12, 0.96; p = 0.04), while
the cardio-oncology and general clinic population were
found to have a similar prevalence (OR 1.34; 95 % CI:
0.55, 3.4; p = 0.5). The overall CAC severity score, of a
possible 996, was 254 in the cardio-oncology clinic, 363 in
conventional cardiology, and 167 in the general clinic
population. In multivariate analysis, the total severity of
CAC was significantly lower in the cardio-oncology clinic
compared with the conventional cardiology clinic (OR
0.33; 95 % CI: 0.11, 1.00; p = 0.05). The total severity of
CAC in the cardio-oncology and general clinic popula-
tions was not significantly different (OR 1.05; 95 % CI:
0.41, 2.72; p = 0.92). Analysis of the extent and severity of
CAC in individual arteries, such as the LMCA and LAD,
Table 1 Baseline characteristics
General Characteristics Cardio-Onc Clinic Cardiology Clinic General clinic population P-value
Total Number of patients 83 83 83
Number of men 35 41 41 0.60
Average age 60.12 60.52 59.69 0.91
Race White = 49 White = 29 White = 34 0.03
Black = 23 Black = 39 Black = 35
Hispanic = 11 Hispanic = 12 Hispanic = 12
Asian = 0 Asian = 2 Asian = 1
Other = 0 Other = 1 Other = 1
Smoking Status Never = 40 Never = 40 Never = 48 0.05
Former = 35 Former = 29 Former = 18
Current = 8 Current = 14 Current = 17
No. with any known CAD, MI, CABG or stent 18 44 6 <0.01
No. with CKD or ESRD 6 31 12 <0.01
No. Family history of MI 37 31 22 0.05
Average systolic BP 127.1 +/- 19.5 126.6 +/- 21.5 131.4 +/- 21.8 0.27
Average diastolic BP 70 +/- 12.2 71 +/- 12.4 77.2 +/- 13.5 <0.01
Average BMI 27.7 +/- 5.6 29.7 +/- 7.2 27.5 +/- 9.7 0.14
No. with HTN or HTN treatment 48 72 50 <0.01
No. with DM or DM treatment 13 29 21 0.02
No. with dyslipidemia or lipid treatment 35 51 27 <0.01
No. on aspirin 19 52 20 <0.01
No. on beta blockers 27 53 18 <0.01
No. on ACEI or ARB 35 33 22 0.08
No. on nitrates 3 4 1 0.4
ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, BMI Body mass index, BP Blood pressure, CABG Coronary artery bypass grafting,
CAD Coronary artery disease, CKD Chronic kidney disease, DM Diabetes mellitus, ESRD End stage renal disease, HTN Hypertension, MI Myocardial infarction
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cardio-oncology patients who received whole chest or left
sided chest radiation to the two control groups revealed
similar results. These patients had higher levels of CAC
than the general population and lower levels of CAC than
the conventional cardiology clinic.
Discussion
In an effort to understand the relative risk of cardiovas-
cular events in cancer patients with cardiac concerns
referred to a cardio-oncology clinic, this single-center
retrospective observational study evaluated the preva-
lence and severity of CAC in these patients, in compari-
son to cardiac patients with no history of cancer referred
to a regular cardiology clinic, and to non-cancer patients
from the general clinic population. Even after matching
for age and sex, controlling for cardiovascular risk fac-
tors including BMI, and time-dependent variable (from
cancer treatment to date of CT scan), patients referred
to the conventional cardiology clinic had higher preva-
lence, extent and severity of CAC compared with thosereferred to the cardio-oncology clinic. There was no sig-
nificant difference in the burden of CAC in the cardio-
oncology clinic compared to the general clinic population.
To our knowledge, this is the first study investigating
the presence and burden of CAC seen on routine chest
CT scans in a cardio-oncology clinic. The study included
a wide range of cancer diagnoses and treatments, along
with a variety of reasons for referral to the cardio-
oncology clinic, mimicking that seen in clinical practice.
A somewhat unexpected finding is that those referred to
the cardio-oncology clinic had less CAC, despite the fact
that about a quarter of them (18 patients) received left
sided or whole chest radiation, which would be expected
to increase the presence and severity of atherosclerosis
[19], and therefore CAC detected on chest CT. A se-
parate analysis comparing only those cardio-oncology
patients who received left-sided or whole chest radiation
revealed that these patients had higher levels of CAC
than the general population, but lower levels of CAC
than the conventional cardiology clinic. These findings
could have been affected by the low number of patients
Table 2 Cancer diagnoses/treatment in the cardio-oncology
population
Cancer Diagnosis/Treatment No. patients %
Breast Cancer 23 27.71 %
Lymphoma 13 15.66 %
Lung Cancer 11 13.25 %
Gynecologic Cancers 11 13.25 %
Multiple Myeloma/Myelodysplastic Syndromes 10 12.05 %
Leukemia 8 9.63 %
Head and Neck Cancer 2 2.4 %
Sarcoma 2 2.4 %
Colorectal Cancer 1 1.2 %
Renal Cell Cancer 1 1.2 %
Neuroendocrine Tumor 1 1.2 %
Chemotherapy alone 46 55.4 %
Chemotherapy plus radiation therapy 30 36.1 %
Radiation alone 3 3.6 %
Left sided radiation for breast cancer 6 7.2 %
Right-sided radiation for breast cancer 6 7.2 %
Chest radiation for lymphoma 5 6.0 %
Chest radiation for lung cancer 7 8.4 %
Table 3 Multivariate odds ratios and 95 % confidence intervals
for CAC presence/extent compared with cardio-oncology
Total CAC Presence:
Cardiology 0.334 (0.12, 0.96) p = 0.04
General clinic population 1.34 (0.55, 3.4) p = 0.5
Total CAC Severity:
Cardiology 0.33 (0.11, 1.00) p = 0.05
General clinic population 1.05 (0.41, 2.72) p = 0.92
CAC Presence in Left Main Coronary Artery:
Cardiology 0.29 (0.1, 0.83) p = 0.02
General clinic population 0.47 (0.19, 1.2) p = 0.16
CAC Severity in Left Main Coronary:
Cardiology 0.19 (0.05, 0.7) P = 0.013
General clinic population 0.16 (0.04, 0.61) p = 0.92
CAC Extent in Left Anterior Descending:
Cardiology 0.36 (0.13, 1.02) p = 0.05
General clinic population 1.36 (0.55, 3.35) p = 0.5
CAC Severity in Left Anterior Descending:
Cardiology 0.39 (0.13–1.23) p = 0.1
General clinic population 1.23 (0.44, 3.42) p = 0.69
Adjusted by number with any known coronary artery disease, myocardial
infarction, coronary artery bypass grafting, number with chronic kidney
disease or end stage renal disease, family history of myocardial infarction,
number with hypertension or hypertension treatment, number with diabetes
mellitus or diabetes treatment, number with dyslipidemia or lipid treatment,
number on aspirin, average systolic BP, average BMI, and age, sex, date of
chest CT scan match
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patients with left sided breast cancer, 5 patients with
lymphoma, and 7 patients with lung cancer), as well as
the limited number of patients in the study overall. Data
are limited on the prevalence of CAC post chest wall
radiation [20], and one small study has suggested
absence/low levels of CAC in patients referred for CT
scanning after radiation therapy for breast cancer [21].
The possible lack of calcification in the radiation plaque
may have something to do with known differences in the
histology of atherosclerosis for the radiation-induced
arterial plaque relative to the more traditional (non-radi-
ation induced) plaque. While the histology of the trad-
itional atherosclerosis involves more macrophage-driven
atheromatous plaque, the process for radiation-induced
atherosclerosis leads to fibrous plaque. Thus, despite its
utility in predicting CHD and CVD events in the general
population, further larger and more diverse studies are re-
quired to evaluate the utility of CAC screening for
radiation-induced heart disease and cardiovascular events.
It is also possible that our results reflect a referral bias
between the two clinics. The patients in the cardiology
group had a significantly higher amount of baseline
CAD. Patients who present to a cardio-oncology clinic
are commonly referred for reasons other than CAD;
such as cardiomyopathy, hypertension and arrhythmias.
Additionally, cardio-oncology clinics are comprised of
non-invasive cardiologists, compared with the conven-
tional cardiology clinic made up of both general and
interventional cardiologists - translating to more severe
CAD. It must be noted that patients with a history of
cancer were excluded from the conventional cardiology
group in this study. As such, cancer patients with CAD
requiring treatment by an interventional cardiologist
were not included in this study. Further investigation, in
a more randomized fashion, is needed before conclu-
sions can be made regarding levels of CAC in patients
with heart disease with and without cancer.
Previous research investigating associations between can-
cer and CAC are limited and have shown mixed results. A
recent study utilizing the Multi-Ethnic Study of Athero-
sclerosis (MESA) cohort found that a diagnosis of cancer
and its treatment was associated with an increased inci-
dence of developing new CAC in both men and women,
even after accounting for atherosclerotic risk factors [22].
This was the first study to investigate the longitudinal
change of CAC with a cancer diagnosis, compared to the
general population. A smaller, cross-sectional cohort study
of 80 breast cancer patients, demonstrated significantly
higher CAC scores prior to receiving radiation therapy,
compared to controls from the MESA cohort. However,
this difference was only significant in the age category 55–
64 years [23]. Studies investigating the effect of cancer
treatment on CAC scores have had mixed results [24, 25].
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patients were selected from a cardio-oncology clinic and a
wide range of cancer types and past treatments were
included. Additionally, our comparison groups consisted of
non-cancer patients selected from the same hospital, rather
than historical controls or published cohort values. Lastly,
we were able to use chest CT scans that had already been
recorded as part of each patient’s past cancer workup.
Limitations of this study should be acknowledged.
First, this was not a prospective, randomized study. The
population studied was a small retrospective cohort
from one single medical center and the small sample
size may have limited the power of our study. Of note,
prior CAC studies have been conducted with a smaller
number of patients. Our inclusion criteria limited the
number of patients at our hospital available for poten-
tial matches. Therefore, the groups are not perfectly
homogenous according to race and sex, although the
difference for sex was not statistically significant. We
included all types of malignancies and prior anti-cancer
treatment histories for which we did not adjust; although
we adjusted for the higher rates of cardiac disease and risk
factors in the general-cardiology group, the possibility of
residual confounding remains. We included CT scans
recorded for a variety of clinical indications with varying
acquisition protocols. However, the scanners included
used similar imaging techniques. Additionally, we demon-
strated good concordance amongst our three readers,
indicating that any variation in scan technique resulted in
the same interpretation. The CT scans were ungated, so
small foci of calcification could have been missed due to
motion artifact from the heart. However, low dose ungated
MDCT has been shown to be reliable for predicting the
presence of CAC and assessment of Agatston score, with
excellent correlation between gated and ungated MDCT
[26]. Lastly, we used a simplified visual CAC scoring
system; and while it is not validated, it has been shown to
be reliable for predicting the presence of CAC and assess-
ment of Agatston score [26]. Studies using simple ordinal
scoring systems, similar to the system used in our study
for the visualization of CAC on ungated-low dose CT
scans recorded for screening and diagnostic purposes have
shown a correlation between CAC severity and cardio-
vascular events and death [5, 27]. The high degree of
concordance in CAC scoring amongst the reviewers
despite differences in experience and CT scanners utilized
demonstrates the ease and robustness of the employed
semi-quantitative technique for its application in a variety
of patient populations and general practice.
Conclusion
Despite being closely matched by age and sex, and
controlling for other major cardiovascular risk factors,
patients referred to our cardio-oncology clinic had similarand less prevalent/severe CAC burden compared with the
general population and conventional cardiology clinics,
respectively. This was an unexpected finding given that a
third of our cardio-oncology clinic population received
radiation therapy known to be associated with long-term
accelerated development of atherosclerosis. It is possible
that differences in atherosclerosis plaque composition
translate to the eventual CAC end-point in coronary
vessels. Whether this translates to less utility of CAC for
CAD screening (or to less overall coronary events) in a
cardio-oncology clinic, is of interest. The cardio-oncology
population receives multiple staging and surveillance
chest CT scans, which could easily translate into a readily
available coronary event risk prediction, if found to be a
useful tool for this purpose. As such, more investigation
into the utility of CAC screening – by dedicated or unded-
icated chest CT scans – for coronary or cardiovascular
events, is warranted in this population.
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